Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken. Watch this short video to learn why!

FDA’s New Classification: Lysosomal Storage Disorder Newborn Screening

$9.99

Discover the FDA’s strategic decision to classify the lysosomal storage disorder newborn screening test system into class II, complete with special controls. This course offers a detailed examination of what this classification means for safety, effectiveness, and regulatory compliance, and how it can open the door to innovative medical solutions while reducing regulatory burdens.

In this course you will learn the following:
* Understand the classification process and criteria for medical devices.
* Identify the special controls applicable to the lysosomal storage disorder newborn screening test system.
* Recognize the impact of this classification on regulatory burdens and patient access to innovative devices.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year.  At the end of the one year term, the course will be set to “inactive”. 

Why This Course is Important
Without this course, learners might miss crucial insights into the FDA’s classification process, leading to potential non-compliance and missed opportunities in bringing innovative newborn screening devices to market.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Lysosomal Storage Disorder Newborn Screening Test System.

Key regulatory references include:

Course SKU
FR-25-1405-1